Efectividad y satisfacción del tratamiento de la dislipidemia con pitavastatinastudio observacional, postautorización, descriptivo y multicéntrico (estudio REINA) / Effectivity and satisfaction with the treatment for dyslipidemia with pitavastatin. Multicentric, descriptive, post authorised and observational study (REINA study)

Introducción: Evaluar la adherencia terapéutica y la satisfacción del paciente con el tratamiento son medidas a considerar para optimizar el control lipídico. El estudio REINA evalúa el grado de satisfacción en pacientes dislipidémicos tratados con pitavastatina. Métodos Estudio observacional, descriptivo, transversal y multicéntrico de ámbito nacional. Se recogieron los siguientes datos: test Morisky-Green y TSQM-9 de pacientes mayores de 18 años con dislipidemia tratada con pitavastatina en las últimas 12 semanas. Resultados Se estudiaron 6.489 pacientes (60,0% varones) de atención primaria (52,7%) y especializada (47,3%), con edad media de 60,9 ± 11,2 años, mediante muestreo aleatorizado. El 72,3% de los pacientes consiguieron un adecuado control con 2 mg/día de pitavastatina. La satisfacción global con la medicación fue de 73,20 (IC 95%: 58,17-87,23) puntos. Los pacientes cumplidores (65%) presentaron mejores datos de satisfacción tomando la medicación (77,70 [IC 95%: 65,20-90,20]), están globalmente más satisfechos (75,00 [IC 95%: 61,50-88,50]) y su satisfacción fue mayor con la eficacia de la medicación (72,50 [IC 95%: 57,70-87,30]) que los no cumplidores (72,70 [IC 95%: 59,30-85,74]; 68,5 [IC 95%: 53,20-83,80] y 67,80 [IC 95%: 53,70-81,90], respectivamente), p < 0,0001, sin diferencias entre los 2 sistemas asistenciales. Conclusiones: La valoración de la satisfacción es un indicador indispensable en la evaluación de servicios dispensados en salud. Los usuarios con mayor grado de satisfacción presentan una mejor adherencia terapéutica, siendo esta relación bidireccional. Las personas satisfechas y cumplidoras obtienen mejores resultados clínicos. Pitavastatina constituye una eficaz alternativa terapéutica en pacientes con dislipidemia

Introduction: Evaluating the therapeutical adherence as well as the patient' satisfaction with the treatment should be considered to optimize lipidic control. The REINA Study evaluates the grade of satisfaction in dyslipidemic patients treated with pitavastatin. Methods: The current study was observational, descriptive, transversal and multi-centric with patients from our country only. The following data were collected in each case: Morisky-Green test and TSQM-9 for patients older than 18years old, with dyslipidemia treated with pitavastatin in the last 12 weeks. Results: We studied 6,489 patients (60.0% males) from Primary Health (52.7%) and Specialised Health (47.3%), with age (mean) = 60.9 ± 11.2 years by aleatory sampling. 72.3% of patients achieved an adequate control with 2 mg/day of pitavastatin. General satisfaction with the treatment was 73.20 points (95% CI: 58.17-87.23). Patients who followed the treatment (65%) showed better data of satisfaction with the drug (77.70 [95% CI: 65.20-90.20]), of global satisfaction (75.00 [95% CI: 61.50-88.50]) and their satisfaction with the drug efficiency was higher (72.50 [95% CI: 57.70-87.30]) than in the patients who did not finish the treatment (72.70 [95% CI: 59.30-85.74]; 68.5 [95% CI: 53.20-83.80] and 67.80 [95%CI: 53.70-81.90], respectively), P < .0001, without any difference between the two primary care systems. Conclusions: The validation of the satisfaction is a crucial indicator in the evaluation of the services offered in health. Patients with the highest grade of satisfaction present better therapeutical adherence, and such a relation is bidirectional. The individuals who are satisfied and who followed the treatment obtained better clinical results. Pitavastatin is an effective therapeutic alternative for patients with dyslipidemia

[Effectivity and satisfaction with the treatment for dyslipidemia with pitavastatin. Multicentric, descriptive, post authorised and observational study (REINA study)]. / Efectividad y satisfacción del tratamiento de la dislipidemia con pitavastatinastudio observacional, postautorización, descriptivo y multicéntrico (estudio REINA).

INTRODUCTION: Evaluating the therapeutical adherence as well as the patient' satisfaction with the treatment should be considered to optimize lipidic control. The REINA Study evaluates the grade of satisfaction in dyslipidemic patients treated with pitavastatin. METHODS: The current study was observational, descriptive, transversal and multi-centric with patients from our country only. The following data were collected in each case: Morisky-Green test and TSQM-9 for patients older than 18 years old, with dyslipidemia treated with pitavastatin in the last 12 weeks. RESULTS: We studied 6,489 patients (60.0% males) from Primary Health (52.7%) and Specialised Health (47.3%), with age (mean) = 60.9 ± 11.2 years by aleatory sampling. 72.3% of patients achieved an adequate control with 2mg/day of pitavastatin. General satisfaction with the treatment was 73.20 points (95% CI: 58.17-87.23). Patients who followed the treatment (65%) showed better data of satisfaction with the drug (77.70 [95% CI: 65.20-90.20]), of global satisfaction (75.00 [95% CI: 61.50-88.50]) and their satisfaction with the drug efficiency was higher (72.50 [95% CI: 57.70-87.30]) than in the patients who did not finish the treatment (72.70 [95% CI: 59.30-85.74]; 68.5 [95% CI: 53.20-83.80] and 67.80 [95% CI: 53.70-81.90], respectively), P < .0001, without any difference between the two primary care systems. CONCLUSIONS: The validation of the satisfaction is a crucial indicator in the evaluation of the services offered in health. Patients with the highest grade of satisfaction present better therapeutical adherence, and such a relation is bidirectional. The individuals who are satisfied and who followed the treatment obtained better clinical results. Pitavastatin is an effective therapeutic alternative for patients with dyslipidemia.